249 related articles for article (PubMed ID: 21386089)
21. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
[TBL] [Abstract][Full Text] [Related]
22. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI).
Guagliumi G; Sirbu V; Musumeci G; Bezerra HG; Aprile A; Kyono H; Fiocca L; Matiashvili A; Lortkipanidze N; Vassileva A; Popma JJ; Allocco DJ; Dawkins KD; Valsecchi O; Costa MA
Circ Cardiovasc Interv; 2010 Aug; 3(4):367-75. PubMed ID: 20647562
[TBL] [Abstract][Full Text] [Related]
23. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
Jensen LO; Maeng M; Thayssen P; Villadsen A; Krusell L; Botker HE; Pedersen KE; Aaroe J; Christiansen EH; Vesterlund T; Hansen KN; Ravkilde J; Tilsted HH; Lassen JF; Thuesen L
EuroIntervention; 2011 Jul; 7(3):323-31. PubMed ID: 21729834
[TBL] [Abstract][Full Text] [Related]
24. Comparison of neointimal hyperplasia and peri-stent vascular remodeling after implantation of everolimus-eluting versus sirolimus-eluting stents: intravascular ultrasound results from the EXCELLENT study.
Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Gwon HC; Ahn T; Chae IH; Yoon JH; Kim HS; Jang Y;
Int J Cardiovasc Imaging; 2013 Aug; 29(6):1229-36. PubMed ID: 23456359
[TBL] [Abstract][Full Text] [Related]
25. Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy.
Maehara A; Mintz GS; Lansky AJ; Witzenbichler B; Guagliumi G; Brodie B; Kellett MA; Parise H; Mehran R; Stone GW
Circulation; 2009 Nov; 120(19):1875-82. PubMed ID: 19858413
[TBL] [Abstract][Full Text] [Related]
26. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
Claessen BE; Beijk MA; Legrand V; Ruzyllo W; Manari A; Varenne O; Suttorp MJ; Tijssen JG; Miquel-Hebert K; Veldhof S; Henriques JP; Serruys PW; Piek JJ
Circ Cardiovasc Interv; 2009 Aug; 2(4):339-47. PubMed ID: 20031737
[TBL] [Abstract][Full Text] [Related]
27. Comparison of sirolimus and paclitaxel-eluting stents for complex coronary lesions: an intravascular ultrasound study.
Cho YK; Hur SH; Kim HT; Kim IC; Park HS; Yoon HJ; Nam CW; Kim H; Han SW; Kim YN; Kim KB
Korean J Intern Med; 2009 Dec; 24(4):323-9. PubMed ID: 19949730
[TBL] [Abstract][Full Text] [Related]
28. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
Stiermaier T; Heinz A; Schloma D; Kleinertz K; Dänschel W; Erbs S; Linke A; Boudriot E; Lauer B; Schuler G; Thiele H; Desch S
Catheter Cardiovasc Interv; 2014 Feb; 83(3):418-24. PubMed ID: 23873579
[TBL] [Abstract][Full Text] [Related]
29. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
[TBL] [Abstract][Full Text] [Related]
30. Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents.
Weissman NJ; Turco MA; Ormiston JA; Mann T; Cannon LA; McGarry TF; Webster MW; Hall JJ; Lucca MJ; Mishkel GJ; Wu CJ; Mandinov L; Dawkins KD
Cardiovasc Revasc Med; 2011; 12(4):247-57. PubMed ID: 21130708
[TBL] [Abstract][Full Text] [Related]
31. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial.
Jensen LO; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Galloe A; Kelbaek H; Lassen JF; Thuesen L
Eur Heart J; 2008 Nov; 29(22):2733-41. PubMed ID: 18832385
[TBL] [Abstract][Full Text] [Related]
32. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.
Miyazawa A; Ako J; Hongo Y; Hur SH; Tsujino I; Courtney BK; Hassan AH; Kandzari DE; Honda Y; Fitzgerald PJ;
Am Heart J; 2008 Jan; 155(1):108-13. PubMed ID: 18082499
[TBL] [Abstract][Full Text] [Related]
33. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
Waseda K; Hasegawa T; Ako J; Honda Y; Grube E; Whitbourn R; Ormiston J; O'Shaughnessy CD; Henry TD; Overlie P; Schwartz LB; Sudhir K; Chevalier B; Gray WA; Yeung AC; Fitzgerald PJ;
Circ J; 2010 Nov; 74(11):2334-9. PubMed ID: 20890052
[TBL] [Abstract][Full Text] [Related]
34. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
Sakata K; Waseda K; Kume T; Otake H; Nakatani D; Yock PG; Fitzgerald PJ; Honda Y
Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
[TBL] [Abstract][Full Text] [Related]
35. Intravascular ultrasound comparison of small coronary lesions between novel guidewire-based sirolimus-eluting stents and conventional sirolimus-eluting stents.
Kume T; Waseda K; Koo BK; Botelho R; Verheye S; Whitbourn R; Meredith I; Worthley S; Hai KT; Yock PG; Azevedo de Oliveira FR; Abizaid A; Fitzgerald PJ; Honda Y
J Invasive Cardiol; 2012 Oct; 24(10):489-93. PubMed ID: 23043031
[TBL] [Abstract][Full Text] [Related]
36. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
[TBL] [Abstract][Full Text] [Related]
37. Impact of stent platform of paclitaxel-eluting stents: assessment of neointimal distribution on optical coherence tomography.
Otake H; Shite J; Shinke T; Miyoshi N; Kozuki A; Kawamori H; Nakagawa M; Nagoshi R; Hariki H; Inoue T; Osue T; Taniguchi Y; Hiranuma N; Nishio R; Kinutani H; Hirata K
Circ J; 2012; 76(8):1880-8. PubMed ID: 22664867
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
39. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
40. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
